A Double-blind, Placebo Controlled Trial of Metformin Treatment in Progressive Multiple Sclerosis
Abstract
The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis
Conditions: Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis.
Primary outcome: number of patients with adverse events between baseline and conclusion (month 0 and month 12); number of patients with laboratory abnormalities between baseline and conclusion (month 0 and month 12); number of patients with new T2 lesions on MRI from baseline to conclusion (month 0 and month 12).
Enrollment: 23 participants.
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 23 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.